生物瓣衰败后再次主动脉瓣置换:STS国家数据库分析
基于STS成人心脏外科数据库,纳入2012至2016年因主动脉生物瓣衰败行孤立再次SAVR的患者,分析趋势与结局。2012至2014年例数增加,2015至2016年显著下降;两时段术后卒中、透析肾衰和手术死亡率无差异。
要点
- 2012至2014年再次SAVR例数增加,2015至2016年显著下降。
- 2015至2016年患者更年轻且STS预测死亡风险评分更低。
- 两时段术后卒中、透析肾衰和手术死亡率无显著差异。
核心结论
- 美国因生物瓣衰败行SAVR的患者数量在下降,尤其在老年和高危患者中。
研究设计与样本
- 基于STS成人心脏外科数据库的回顾性趋势分析,纳入2012年1月至2016年12月因主动脉生物瓣衰败行孤立再次SAVR的患者。
主要发现
- 再次SAVR例数从2012年782例增至2013年844例和2014年900例,相对变化+7.25%。
临床怎么用
- 生物瓣衰败患者的外科再干预选择需结合年龄、风险和2015年后瓣中瓣TAVR的可及性综合评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This study was conducted to determine the current nationwide trends and outcomes of reoperative surgical aortic valve replacement (SAVR) performed for a degenerated bioprosthesis. METHODS: Data from The Society of Thoracic Surgeons (STS) Adult Cardiac Surgery Database were used. All patients who underwent isolated reoperative SAVR for a degenerated aortic bioprosthesis between January 2012 and December 2016 were included. Patients who had other concomitant cardiac surgery procedures or active endocarditis were excluded. Changes during this period were tracked with trend analyses. RESULTS: The number of patients undergoing SAVR for bioprosthetic failure increased substantially between 2012 and 2014 (782 in 2012 to 844 in 2013 and to 900 in 2014; relative change, +7.25%); this trend reversed significantly between 2015 and 2016 (decreased to 873 in 2015 and to 840 in 2016; relative change, -3.4%; P = .005). Patients were older in 2012-2014 (65.80 ± 13.52 years) compared with 2015-2016 (64.45 ± 12.91 years; P = .001). Mean STS-predicted mortality risk score decreased from 4.55% in 2012-2014 to 4.25% in 2015-2016 (P = .001). There was no difference in postoperative stroke (1.80% vs 1.80%, P = .87), renal failure requiring dialysis (2.7% vs 2.8%, P = .69), or operative mortality (3.5% vs 4.0%, P = .36) after reoperative SAVR in 2012-2014 and 2015-2016, respectively. CONCLUSIONS: The number of patients undergoing SAVR for a degenerated bioprosthesis is decreasing in the United States, particularly among older and high-risk patients. These trends may reflect the adoption of valve-in-valve transcatheter aortic valve replacement for a degenerated bioprosthesis after its United States Food and Drug Administration approval in 2015.
引用
- Kalra A, Raza S, Hussain M, et al. Aortic Valve Replacement in Bioprosthetic Failure: Insights From The Society of Thoracic Surgeons National Database. Ann Thorac Surg. 2019. PMID: 31557477. doi:10.1016/j.athoracsur.2019.08.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。